- Clinical Technology
- Adult Immunization
- Hepatology
- Pediatric Immunization
- Screening
- Psychiatry
- Allergy
- Women's Health
- Cardiology
- Pediatrics
- Dermatology
- Endocrinology
- Pain Management
- Gastroenterology
- Infectious Disease
- Obesity Medicine
- Rheumatology
- Nephrology
- Neurology
- Pulmonology
AHA Statement on Obesity and CVD: 10 Key Points, to Start
The links between obesity and cardiovascular disease are many, including direct cause and effect. Click through the 10-slide summary of a new AHA statement for a first look.
"... the trends in obesity prevalence in the United States and around the world highlight the significant impact that obesity will continue to have on CVD incidence and prevalence globally."
The American Heart Association's recent publication, "Obesity and cardiovascular disease: a scientific statement from the American Heart Association" reflects the already large and now rapidly growing body of evidence that ever-more precisely links obesity with cardiovascular (CV) risk factors as well as with CV disease (CVD) and mortality independently of other CV risk factors.
The new statement focuses on the impact of obesity on the pathophysiology, diagnosis, treatment, and clinical outcomes of ASCVD, heart failure (HF), and arrhythmias and begins with a review of recent data linking abdominal obesity and visceral adiposity to CVD risk.
As a preview, we summarized in a slide show the statement's 10 key points as highlighted by the American College of Cardiology.
FDA Approves First Oral GLP-1 Receptor Agonist for Chronic Weight Management
December 23rd 2025The FDA approved once-daily oral semaglutide 25 mg for chronic weight management and long-term weight maintenance in adults with obesity or overweight, based on data from the OASIS clinical trial program.
Phase 3 Data Support Oral Orforglipron for Weight Maintenance After GLP-1–Based Weight Loss
December 19th 2025Topline Phase 3 ATTAIN-MAINTAIN data show oral orforglipron met primary and key secondary endpoints for weight maintenance after prior GLP-1–based injectable therapy in adults with obesity.
